Erectile dysfunction prevalence globally is noticeably high. This is accompanied by an increase in the use of nutraceuticals for male enhancement. However, the global market is invaded by counterfeit and adulterated nutraceuticals claimed to be of natural origin sold with a therapeutic claim. The objective of this article is to review male enhancement nutraceuticals worldwide with respect to claim, adulterants, and safety. The definition of such products is variable across countries. Thus, the registration procedures differ as well. This facilitates the manipulation of the process, which leads to widespread adulterated and counterfeit products without control. The tele-advertisement and Internet pharmacies aided the widespread sale of male enhancement nutraceuticals, unfortunately, the spurious ones. Finally, based on literature, most of these products were found to be adulterated with active pharmaceutical ingredients (API) and mislabeled as being natural. These products represent a major health hazard for consumers due to lack of clear regulations.
Continuous manufacturing (CM) has the potential to provide pharmaceutical products with better quality, improved yield and with reduced cost and time. Moreover, ease of scale-up, small manufacturing footprint and on-line/in-line monitoring and control of the process are other merits for CM. Regulating authorities are supporting the adoption of CM by pharmaceutical manufacturers through issuing proper guidelines. However, implementation of this technology in pharmaceutical industry is encountered by a number of challenges regarding the process development and quality assurance. This article provides a background on the implementation of CM in pharmaceutical industry, literature survey of the most recent state-of-the-art technologies and critically discussing the encountered challenges and its future prospective in pharmaceutical industry.
The global CNS pharmaceutical market is expected to grow significantly, overtaking the cardiovascular therapeutics market in the next 10 years. Although much work has been devoted to finding drugs that can cross the BBB into the brain, no single approach has worked for all drugs. The lack of technology to effectively cross the BBB or the blood-tumor barrier prevents researchers from providing effective therapeutics for most patients with brain disorders. Drug loaded nanoparticles (NPs) can hide the unfavorable drug's physicochemical characteristics, which hinders its ability to cross the BBB. In this study, we investigate the effect of different surfactant coatings, in a single or a blend form, on polymeric NPs loaded with model dyes and drugs on the brain drug uptake. Different NP formulations are conveyed using different cores ((Poly Lactic-co-Glycolic Acid (PLGA) and Chitosan) and coat materials (tweens, poloxamers, thiamine, polyethylene glycol (PEG), propylene glycol (PG) and spans). Chitosan core was formulated via ionic gelation technique. PLGA core was formulated via solvent evaporation technique. Different surfactants with different HLB (Hydrophilic Lipophilic Balance) values were applied as coating materials for the NPs. All NP formulations were characterized with respect to their size; charge, stability, in-vitro drug release to reach the optimal formulation. Female CD-1 mice were used to evaluate the drug brain uptake. Harvesting of the brain takes place within 60 seconds of animal sacrifice. Animals were euthanized, and brain tissue were removed and homogenized. Concentration of Rodamine B (Model dye) in the brain homogenates was analyzed via HPLC. The developed uncoated Chitosan NPs are in the size range of 50-100 nm with small polydispersity Index (PDI) (∼ 0.3) and a reproducible zeta potential of ∼ +19mV. After coating with tween-80 the zeta potential has decreased to -5 mV. The Tween-80 coated NPs were visualized via Transmission Electron Microscope (TEM). The particle size of the coated NP increased over the uncoated one from ∼ 100 nm to (150 - 200 nm). Finally, brain RodamineB concentration was significantly higher in case of tween-80 coated Chitosan and PLGA compared to uncoated NPs. The use of the novel drug carrier systems for drug targeting to brain is a promising alternative to conventional CNS therapy. The currently used polymers in this study are nontoxic, biodegradable, and biocompatible. The surfactant coated NPs for brain drug delivery is a promising technique to enhance brain uptake. The use of the surfactant coat could aid the solubilization of endothelial cell membrane lipids leading to membrane fluidization and enhanced drug permeability at the BBB. Citation Format: Mohamed I. Nounou, Salma Saudi, Ola Elnoweam, Dalia Alian, Amal El-Kamel. Surfactant coated nanoparticles for brain metastases: A brain uptake perspective. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B39.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.